PDF(1422 KB)
Clinical effects of different therapeutic regimens for Helicobacter pylori infection in children
ZHU Xiang-Li, LIU Zheng, WU Zhong-Qiang, LI Dong, JIANG Ai-Ping, YU Gui-Xia
Chinese Journal of Contemporary Pediatrics ›› 2017, Vol. 19 ›› Issue (6) : 672-676.
PDF(1422 KB)
PDF(1422 KB)
Clinical effects of different therapeutic regimens for Helicobacter pylori infection in children
Objective To investigate the clinical effects of sequential therapy, triple therapy, sequential therapy combined with Lactobacillus, and triple therapy combined with Lactobacillus in the eradication of Helicobacter pylori (H.pylori) infection in children. Methods A total of 416 children with H.pylori infection were randomly assigned to sequential group (102 children), triple group (100 children), sequential-Lactobacillus group (109 children), and triple-Lactobacillus group (105 children). The clinical outcome, H.pylori eradication rate, cost-effect ratio, and incidence of adverse events were compared between the four groups. Results The sequential-Lactobacillus and triple-Lactobacillus groups had significantly better clinical outcomes than the sequential group and the triple group (P < 0.05). The sequential-Lactobacillus group had the highest marked response rate, followed by the triple-Lactobacillus group. The triple group had the lowest marked response rate. The sequential-Lactobacillus group also had the highest H.pylori eradication rate, followed by the triple-Lactobacillus group. The triple group had the lowest H.pylori eradication rate (P < 0.05). The sequential group had the lowest cost-effect ratio, followed by the sequential-Lactobacillus group. The triple group had the highest cost-effect ratio (P < 0.01). The sequential-Lactobacillus group had the lowest incidence rate of adverse events, followed by the triple-Lactobacillus group. The triple group had the highest incidence rate. Conclusions Sequential therapy combined with Lactobacillus seems to be the best regimen for the eradication of H.pylori infection in children.
Helicobacter pylori / Treatment / Lactobacillus / Clinical effect / Child
[1] Rowland M, Daly L,Vaughan M, et al. Age-specific incidence of Helicobacter pylori[J]. Gastroenterology, 2006, 130(1):65-72.
[2] 张双红, 朱萱. 儿童幽门螺杆菌感染研究进展[J].临床儿科杂志, 2015, 33(4):391-395.
[3] Nguyen TV, Bengtsson C, Nguyen GK, et al. Age as risk factor for Helicobacter pylori recurrence in children in Vietnam[J]. Helicobacter, 2012, 17(6):452-457.
[4] 胡伏莲. 幽门螺杆菌感染的流行病学[J]. 中国医刊, 2007, 42(2):17-18.
[5] Liu G, Xu X, He L, et al. Primary antibiotic resistance of Heliobacter pylori isolated from Beijing children[J]. Helicobacter, 2011, 16(5):356-362.
[6] 王玉环, 黄瑛, 王传清, 等. 儿童结节性胃炎幽门螺杆菌耐药性分析[J]. 临床儿科杂志, 2014, 32(10):903-906.
[7] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌科研协作组. 中国幽门螺杆菌耐药状况以及耐药对治疗的影响-全国多中心临床研究[J]. 胃肠病学, 2007, 12(9):525-530.
[8] 张勇, 李锦霞. 布拉酵母菌对三联疗法治疗儿童幽门螺杆菌感染的影响[J]. 临床儿科杂志, 2012, 30(10):928-931.
[9] Zou J, Dong J, Yu X. Meta-analysis:Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Heliobacter pylorier adication[J]. Heliobacter, 2009, 14(5):97-107.
[10] Li S, Huang XL, Sui JZ, et al. Meta-analysis randomized controlled trials on the efficacy of probiotics in Heliobacter pylori eradication therapy in children[J]. Eur J Pediatr, 2014, 173(2):153-161.
[11] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组. 第四次全国幽门螺杆菌感染处理共识报告[J]. 中华内科杂志, 2012, 51(10):832-837.
[12] Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Heliobacter pylori infection:a comprehensive review of the literature[J]. Heliobacter, 2010, 15(2):79-87.
[13] 徐龙, 刘子仲, 舒建昌. 儿童序贯疗法与传统三联疗法根除儿童幽门螺杆菌的疗效比较[J]. 中国当代医药, 2013, 20(8):49-51.
[14] 张运玲, 朱朝敏. 儿童幽门螺杆菌感染的诊断与治疗[J]. 实用儿科临床杂志, 2012, 27(19):1541-1544.
[15] 付尚勤, 谢步善, 万伦常. 益生菌联合标准三联疗法治疗Hp阳性消化性溃疡的疗效[J]. 实用临床医药杂志, 2014, 18(13):111-112.
[16] Khani S, Hosseini HN, Taheri M, et al. Probiotics as an alternative strategy for prevention and treatment of human diseases:a review[J]. Inflamm Allergy Drug Targets, 2012, 11(2):79-89.
[17] Hsieh P, Tsai YC, Chen YC, et al. Eradication of Helicobacter pylori infection by the probiotic strains lactobacillus johnsonii MH-68 and L. salivarius ssp. salicinius AP-32[J]. Heliobacter, 2012, 17(6):466-477.
[18] 袁泉, 徐秀芬, 刘桂芳. 双歧杆菌三联活菌胶囊联合四联疗法治疗幽门螺杆菌的临床观察[J]. 中国实用医药, 2016, 11(5):1-3.
[19] Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Heliobacter pylori infection[J]. World J Gastroenterol, 2012, 18(43):6302-6307.
[20] 谭晓林, 谢彩虹, 赵超, 等. 复合乳酸菌联合三联疗法及四联疗法根治幽门螺杆菌的疗效[J]. 临床医学工程, 2015, 2(8):1054-1055.
[21] Zojaji H, Ghobakhlou M, Rajabalinia H, et al. The efficacy and safety of adding the probiotic Saccharomyces boulardiito standard triple therapy for eradication of H.pylori:a randomized controlled trial[J]. Gastroenterol Hepatol Bed Bench, 2013, 6(Suppl 1):S99-S104.
[22] 陈太平, 吴冬妮, 陈曙东, 等. 药物经济学的评价方法及应用情况[J]. 东南国防医药, 2015, 17(6):626-628.
